Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]

The authors regret that the Conflict of Interest Statement was missing important information.

The Conflict of interest should read:

Dr. Kevinkumar Kansagra is an employee at Zydus Cadila.

The authors would like to apologise for any inconvenience caused. This correction has now been updated in the main article online.